Multiple sclerosis symptoms improved by new cellular immunotherapy

Written by Lucy Cliff, Future Science Group

A new cellular immunotherapy treatment that targets the Epstein-Barr virus (EBV) has been shown to improve the symptoms and quality of life for people with multiple sclerosis (MS) in a recent Phase I clinical trial. Results of an open-label, Phase I clinical trial conducted at the University of Queensland (Brisbane, Australia), have shown that a new cellular immunotherapy improves the symptoms of multiple sclerosis for the majority of patients. This represents the first time a T-cell immunotherapy has been used to treat an autoimmune disease and could potentially help change the lives of those with MS in the future. The...

To view the full article, please register now for access

It's completely free